Lupin Limited has reportedly received the European Commission’s approval for its specialty drug NaMuscla used in the treatment of a rare neuromuscular disorder. As per trusted sources, Lupin is preparing to launch NaMuscla in Germany and the UK in the first quarter of 2019, while seeking partners to market the drug in the remaining European territories.
NaMuscla, or rather mexiletine, is commonly used for the treatment of symptoms of myotonia in adults suffering from nondystrophic myotonic disorders. NDM disorders comprise a group of rare and genetic neuromuscular disorders which result in the inability to relax the muscles after voluntary contraction.